 BOSTON--BUSINESS WIRE--Gamida Cell Ltd. Nasdaq: GMDA, a leading cellular and immune therapeutics company, today announced that updated data from the ongoing Phase 1 clinical study of GDA-201, an investigational, natural killer NK cell-based cancer immunotherapy for the treatment of patients with non-Hodgkin lymphoma, will be presented in an oral presentation at the American Society of Hematology ASH 62nd Annual Meeting, which is being held virtually from December 5-8, 2020. NK cell immu 